Page 6 - Moves Out News Today : Breaking News, Live Updates & Top Stories | Vimarsana

4.3.3 Diagnostics Moves Out of the Hospital 4.3.4 Disruption Looms 5. PCR Recent Developments 5.1.1 Importance of These Developments Scope Fluidics Secures €6.2M Supporting Rapid MDx Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond' Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition HelixBind Receives $3M NIH Grant to Expand Bloodstream Infection Dx Platform Israel's Nucleix Targeting US Market With Noninvasi...

4.3.3 Diagnostics Moves Out of the Hospital 4.3.4 Disruption Looms 5. PCR Recent Developments 5.1.1 Importance of These Developments 5.1.2 How to Use This Section Scope Fluidics Secures ?6.2M Supporting Rapid MDx Quidel Expects SARS-CoV-2 Testing Demand to Continue 'Through 2022, and Beyond' Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition HelixBind Receives $3M NIH Grant to Expand Bloodstream Infection Dx Platform Israel's Nucleix Target...

Share this article Share this article ResearchAndMarkets.com's offering. Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID-19 Pandemic has increased the sepsis death toll. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life-saving diagnostics can command a premium in the market, especially deaths related to COVID-19 infections. Understand the different drivers of this huge global diagn...